Are Drug Companies Living Up to Their Human Rights Responsibilities? Moving Toward Assessment

English version České info

Background to the debate:
The human rights responsibilities of drug companies have been considered for years by nongovernmental organizations, but were most sharply defined in a report by the UN Special Rapporteur on the right to health, submitted to the United Nations General Assembly in August 2008. The “Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines” include responsibilities for transparency, management, monitoring and accountability, pricing, and ethical marketing, and against lobbying for more protection in intellectual property laws, applying for patents for trivial modifications of existing medicines, inappropriate drug promotion, and excessive pricing. Two years after the release of the Guidelines, the PLoS Medicine Debate asks whether drug companies are living up to their human rights responsibilities. Sofia Gruskin and Zyde Raad from the Harvard School of Public Health say more assessment is needed of such responsibilities; Geralyn Ritter, Vice President of Global Public Policy and Corporate Responsibility at Merck & Co. argues that multiple stakeholders could do more to help States deliver the right to health; and Paul Hunt and Rajat Khosla introduce Mr. Hunt's work as the UN Special Rapporteur on the right to the highest attainable standard of health, regarding the human rights responsibilities of pharmaceutical companies and access to medicines.

Vyšlo v časopise: Are Drug Companies Living Up to Their Human Rights Responsibilities? Moving Toward Assessment. PLoS Med 7(9): e32767. doi:10.1371/journal.pmed.1000310
Kategorie: The PLoS Medicine Debate
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000310

Souhrn

Zdroje

1. Citizenship@Novartis Available: http://www.corporatecitizenship.novartis.com/business-conduct/index.shtml. Accessed 25 February 2010

2. CollierJ

WanderleyL

2005 Thinking for the future: Global corporate responsibility in the twenty-first century. Futures 37 169 182

3. Medecins Sans Frontieres Campaign for access to essential medicines. Available: http://www.msfaccess.org/. Accessed 29 September 2009

4. Committee on Economic, Social and Cultural Rights 2000 The right to the highest attainable standard of health: General Comment 14. E/C.12/2000/4. Available: http://www.unhchr.ch/tbs/doc.nsf/0/40d009901358b0e2c1256915005090be?Opendocument. Accessed 5 October 2009

5. YaminAE

2003 Not just a tragedy: Access to medications as a right under international law. Boston Univ Int Law J 21 325 371

6. HuntP

KhoslaR

2008 The human right to medicines. Sur 5 99 115

7. FordN

WilsonD

Costa ChavesG

LotrowskaM

KannikarK

2007 Sustaining access to antiretroviral therapy in the less-developed world: Lessons from Brazil and Thailand. AIDS 21 Suppl 4 S21 29

8. CulletP

2005 Patents and medicines: The relationship between TRIPS and the human right to health.

GruskinS

GrodinMA

AnnasGJ

MarksSP

Perspectives on health and human rights New York Routledge 179 202

9. WeissbrodtD

KrugerM

2003 Norms on the responsibilities of transnational corporations and other business enterprises with regard to human rights. Am J Int Law 97 901 902

10. United Nations 2003 Norms on the responsibilities of transnational corporations and other business enterprises with regard to human rights. E/CN.4/Sub.2/2003/12/Rev.2. Available: http://www.unhchr.ch/huridocda/huridoca.nsf/%28Symbol%29/E.CN.4.Sub.2.2003.12.Rev.2.En. Accessed 14 May 2010

11. HuntP

2006 Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. United Nations General Assembly. A/61/338. Available: www.atmindex.org/download/10. Accessed 25 February 2010

12. HuntP

2008 Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. United Nations General Assembly. A/63/263. Available: http://daccess-ods.un.org/TMP/1358159.4824791.html. Accessed 25 February 2010

13. HuntP

2009 Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Annex Mission to GlaxoSmithKline. United Nations General Assembly. A/HRC/11/12/Add.2. Available: 198.170.85.29/Paul-Hunt-report-on-GSK-5-May-2009.pdf. Accessed 25 February 2010

14. RuggieJ

2009 Report of the Special Representative of the Secretary-General on the issue of human rights and transnational corporations and other business enterprises: Business and human rights: Towards operationalizing the “protect, respect and remedy” framework. United Nations General Assembly. A/HRC/11/13. Available: http://www2.ohchr.org/english/bodies/hrcouncil/docs/11session/A.HRC.11.13.pdf. Accessed 25 February 2010

15. LiangBA

2006 Fade to black: Importation and counterfeit drugs. Am J Law Med 32 279 323

16. MurphySD

2005 Taking multinational corporate codes of conduct to the next level. Columbia J Transl Law 43 389 343

17. ShrettaR

WaltG

BrughaR

SnowRW

2001 A political analysis of corporate drug donations: The example of Malarone in Kenya. Health Policy Plan 16 161 170

18. WilliamsOF

2004 The UN Global Compact: The challenge and the promise. Bus Ethics Q 14 755 774

19. UNITAID. Working groups Available: http://www.unitaid.eu/en/Working-groups.html. Accessed 25 February 2010

20. SimonsP

2004 Corporate voluntarism and human rights: The adequacy and effectiveness of voluntary self-regulation regimes. Relations Industrielles/Industrial Relations 59 101 141

21. UttingP

2007 CSR and equality. Third World Q 28 697 712

22. CetindamarD

KristofferH

2007 Corporate social responsibility practices and environmentally responsible behavior: The case of the United Nations Global Compact. J Bus Ethics 76 163 176

23. LeeM

KohlerJ

2010 Benchmarking and transparency: Incentives for the pharmaceutical industry's corporate social responsibility. J Bus Ethics 95 641 658

24. NwakaS

2005 Drug discovery and beyond: The role of public-private partnerships in improving access to new malaria medicines. Trans R Soc Trop Med Hyg 99 S20 S29

25. GustavsenK

HansonC

2009 Progress in public-private partnerships to fight neglected diseases. Health Aff 28 1745 1749

26. KoivusaloM

MackintoshM

2009 Global public action in health and pharmaceutical policies: Politics and policy priorities. The Open University. Innovative Knowledge Development working paper No. 45

27. HerxheimerA

2003 Relationships between the pharmaceutical industry and patients' organizations. BMJ 326 1208 1210

28. SmithR

2005 Curbing the influence of the drug industry: A British view. PLoS Med 2 e241 doi:10.1371/journal.pmed.0020241